Types of Research
- (-) Remove East Africa Region and Selected Countries filter East Africa Region and Selected Countries
- (-) Remove Environment & Climate Change filter Environment & Climate Change
- (-) Remove Risk, Preferences, & Decision-Making filter Risk, Preferences, & Decision-Making
- (-) Remove Aid & Other Development Finance filter Aid & Other Development Finance
- (-) Remove Global & Regional Public Goods filter Global & Regional Public Goods
- (-) Remove Southern Africa Region and Selected Countries filter Southern Africa Region and Selected Countries
- (-) Remove 2011 filter 2011
- (-) Remove Gender filter Gender
- (-) Remove Research Brief filter Research Brief
- (-) Remove 2018 filter 2018
- (-) Remove Research & Development filter Research & Development
- (-) Remove Global filter Global
- (-) Remove Literature Review filter Literature Review
The private sector is the primary investor in health research and development (R&D) worldwide, with investment annual investment exceeding $150 billion, although only an estimated $5.9 billion is focused on diseases that primarily affect low and middle-income countries (LMICs) (West et al., 2017b). Pharmaceutical companies are the largest source of private spending on global health R&D focused on LMICs, providing $5.6 billion of the $5.9 billion in total private global health R&D per year. This report draws on 10-K forms filed by Pharmaceutical companies with the U.S. Securities and Exchange Commission (SEC) in the year 2016 to examine the evidence for five specific disincentives to private sector investment in drugs, vaccines and therapeutics for global health R&D: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed costs for research and manufacturing, and imperfect markets. 10-K reports follow a standard format, including a business section and a risk section which include information on financial performance, investment options, lines of research, promising acquisitions and risk factors (scientific, market, and regulatory). As a result, these filings provide a valuable source of information for analyzing how private companies discuss risks and challenges as well as opportunities associated with global health R&D targeting LMICs.
Agriculture is a principal source of livelihood for the Tanzanian population. Agriculture provides more than two-thirds of employment and almost half of Tanzania‘s GDP. Women play an essential role in agricultural production. The sector is characterized as female-intensive, meaning that women comprise a majority of the labor force in agriculture (54%). This brief reviews the academic and grey literature on gender and agriculture in Tanzania, providing an overview on the structure of households, the household structure of agricultural production, information on women’s crops, and gender and land rights in Tanzania. We conclude with a summary of challenges to women in agriculture, and of potential implications for women of advancements in production technology and other economic opportunities at the household level.
This brief presents selected material from the Fourth African Agricultural Markets Program (AAMP) policy symposium, Agricultural Risks Management in Africa: Taking Stock of What Has and Hasn’t Worked, organized by the Alliance for Commodity Trade in Eastern and Southern Africa and the Common Market for Eastern and Southern Africa that took place in Lilongwe, Malawi, September 6-10, 2010. We draw almost exclusively from Rashid and Jayne’s summary, “Risk Management in African Agriculture: A review of experiences.” This article summarizes across the background papers, with major findings grouped into three broad categories: cross cutting, government-led policies, and modern instruments.